Pumping iron: Revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease

Clinical Nephrology

Volumn 77, Issue 3, 2012, Pages 188-195

  Singh, Neeraj ^a   Agarwal, Anil K ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Anemia of CKD; End stage renal disease; Intravenous iron; Iron deficiency

Indexed keywords

ANTIANEMIC AGENT; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; IRON; IRON DEXTRAN;

ANEMIA; ARTICLE; BACTEREMIA; DRUG FORMULATION; DRUG HYPERSENSITIVITY; HUMAN; IMMUNE DYSREGULATION; IRON DEFICIENCY; IRON OVERLOAD; IRON THERAPY; KIDNEY FAILURE; NONHUMAN; OUTCOME ASSESSMENT; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; PATIENT SELECTION; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANEMIA, IRON-DEFICIENCY; CHEMISTRY, PHARMACEUTICAL; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; PATIENT SELECTION; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84859514152     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107266     Document Type: Article

References (49)

1. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Executive Summary. Am J Kidney Dis. 2006; 47 (Suppl 3): S11-S145.
2. Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006; 1 (Suppl 1): S9-S18.
3. Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis. 1999; 34 (Suppl 2): S40-S46.
4. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007; 18: 975-984.
5. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032.
6. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098.
7. Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis. 2009; 16: 143-151.
8. Silverberg DS. The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome. Heart Fail Rev. 2010; 16: 609-614.
9. Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care. 2010; 33: 2310-2313.
10. Agarwal R. Nonhematological benefits of iron. Am J Nephrol. 2007; 27: 565-571.
11. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronickidney disease. Clin Med Res. 2008; 6: 93-102.
12. Anirban G, Kohli HS, Jha V, Gupta KL, Sakhuja V. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail. 2008; 30: 629-638.
13. Yee J, Besarab A. Iron sucrose: the oldest iron therapy becomes new. Am J Kidney Dis. 2002; 40: 1111-1121.
14. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol. 1998; 9: 655-663.
15. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant. 1990; 5: 130-134.
16. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol. 2002; 57: 457-461.
17. Ganguli A, Kohli HS, Khullar M, Lal Gupta K, Jha V, Sakhuja V. Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. Ren Fail. 2009; 31: 106-110.
18. Puntarulo S. Iron, oxidative stress and human health. Mol Aspects Med. 2005; 26: 299-312.
19. Agarwal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int. 2006; 69: 1259-1263.
20. Gülçelik NE, Kayataş M. Importance of serum ferritin levels in patients with renal failure. Nephron. 2002; 92: 230-231.
21. Agarwal R, Rizkala AR, Kaskas MO, Minasian R, Trout JR. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int. 2007; 72: 638-642.
22. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004; 65: 2279-2289.
23. Hsiao PJ, Wang SC, Wen MC, Diang LK, Lin SH. Fanconi syndrome and CKD in a patient with paroxysmal nocturnal hemoglobinuria and hemosiderosis. Am J Kidney Dis. 2010; 55: e1-e5.
24. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009; 94: 2332-2337.
25. Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009; 46: 167-169.
26. Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009; 45: 814-816.
27. Merono T, Rosso LG, Sorroche P, Boero L, Arbelbide J, Brites F. High risk of cardiovascular disease in iron overload patients. Eur J Clin Invest. 2010; 41: 479-486.
28. Erdemoglu AK, Ozbakir S. Serum ferritin levels and early prognosis of stroke. Eur J Neurol. 2002; 9: 633-637.
29. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008; 52: 897-906.
30. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50: 1694-1699.
31. Macdougall IC. Evolution of iv iron compounds over the last century. J Ren Care. 2009; 35 (Suppl 2): 8-13.
32. K/DOQI, National Kidney Foundation. Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2000; 35 (Suppl 2): S1-S140.
33. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996; 28: 529-534.
34. Sinha S, Chiu DY, Peebles G, Kolakkat S, Lamerton E, Fenwick S, Kalra PA. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease. J Ren Care. 2009; 35: 67-73.
35. Wish JB, Fourtner P, Ghaddar S, Moore GM. The biological and economic value of oral organic iron in maintenance dialysis. Nephrol News Issues. 2002; 16: 32-33, 37-39.
36. Al-Mueilo SH. Beneficial effects of maintenance intravenous iron saccharate in hemodialysis patients. Saudi J Kidney Dis Transpl. 2005; 16: 146-153.
37. Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung. 1996; 46: 615-621.
38. Pai AB, Nielsen JC, Kausz A, Miller P, Owen JS. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects. Clin Pharmacol Ther. 2010; 88: 237-242.
39. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2010; 27: 1599-1607.
40. Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int. 2010; 14: 47-54.
41. Gupta A, Amin NB, Besarab A, Vogel SE, Divine GW, Yee J, Anandan JV. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int. 1999; 55: 1891-1898.
42. Dukkipati R, Kalantar-Zadeh K. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients? Nephrol News Issues. 2007; 21: 34-38.
43. Stancu S, Bârsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol. 2010; 5: 409-416.
44. Stancu S, Stanciu A, Zugravu A, Bârsan L, Dumitru D, Lipan M, Mircescu G. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis. 2010; 55: 639-647.
45. Flanagan JM, Truksa J, Peng H, Lee P, Beutler E. In vivo imaging of hepcidin promoter stimulation by iron and inflammation. Blood Cells Mol Dis. 2007; 38: 253-257.
46. Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant. 2000; 15: 1827-1834.
47. Schwenk MH. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy. 2010; 30: 70-79.
48. Shah SV, Rajapurkar MM. The role of labile iron in kidney disease and treatment with chelation. Hemoglobin. 2009; 33: 378-385.
49. Agarwal R, Leehey DJ, Olsen SM, Dahl NV. Proteinuria Induced by Parenteral Iron in Chronic Kidney Disease - A Comparative Randomized Controlled Trial. Clin J Am Soc Nephrol. 2010; 6: 114-121.